As president and CEO of newly formed Canopy Health Innovations, a spin off of Canopy Group (TSX:WEED), a world leading diversified cannabis company, Marc Wayne is a pioneer of the medical cannabis sector. He was a co-founder of Bedrocan Canada, one of Canada’s first licensed producers of medical cannabis, and founding chairman of the Cannabis Canada Association, a trade group with 17 licensed producers. Mr. Wayne also was instrumental in developing the Canadian Consortium for the Investigation of Cannabinoids, a global innovator in education and research on medical cannabis. In this interview with BioTuesdays.com, Mr. Wayne discusses the potential of cannabis-based treatments and how they can offer alternatives to traditional medicines, avoid negative side effects and be disruptive to the pharmaceuticals sector.
Medicure (TSXV:MPH) intends to leverage its unique sales and marketing model, which has fueled the growth of its Aggrastat IV platelet inhibitor, as it brings new generic products into its cardiovascular portfolio.
Medicenna Therapeutics (TSXV:MDNA) is advancing a targeted dual-action immunotherapeutic, MDNA55, that consists of an engineered version of interleukin-4 (IL-4) plus a tumor-killing cytotoxin for the treatment of recurrent glioblastoma, the most common and uniformly fatal form of brain cancer.
As the founder and CEO of Buyins.net, Thomas Ronk has created a proprietary database and trading strategy based on short sale timing and sales data that was not accessible to anyone prior to January 2005. As a registered representative of Transamerica Financial Resources, a division of Transamerica, Mr. Ronk managed more than $150-million in equity accounts from 1993 until 1998. He has 27 years of trading experience and is the principal of Century Pacific Investments, a registered investment advisor in California. Prior to the investment business, Mr. Ronk studied Electrical Engineering and Computer Science at the University of California at San Diego. In this interview with BioTuesdays, Mr. Ronk discusses manipulative short selling and how his company helps clients to analyze and develop a plan to deal with it.
Following a meeting with the FDA last month, Microbix Biosystems (TSX:MBX) is entertaining expressions of interest from potential partners to license or acquire its anti-clotting urokinase drug, which has been rebranded as Kinlytic, and also provide funding for its re-launch in the U.S. market.
With a burgeoning pipeline of pharmaceutical oral films, IntelGenx’s (OTCQX:IGXT; TSXV:IGX) business development strategy is focused on partnering its product pipeline along with actively meeting with potential partners to explore manufacturing opportunities, and continuing to build its product pipeline jointly with R&D.
As a co-founder and chief technical officer of closely held EyeKor, which helps clients navigate the ever-changing landscape of ophthalmic clinical trials, Dr. Yijun Huang, a bioengineering executive, cut his teeth developing software and hardware solutions for ophthalmic imaging applications, both in academic and industrial situations. They include VP of engineering at Topcon Medical Systems, a major Japanese manufacturer of ophthalmic devices. He was also a member of Fundus Photograph Reading Center at the University of Wisconsin-Madison, which acts as a central imaging lab collecting and interpreting images from various ophthalmic clinical trials. In this interview with BioTuesdays.com, Dr. Huang discusses EyeKor’s Excelsior software platform for imaging data management, its market penetration and a recent collaboration with Clearside Biomedical (NASDAQ:CLSD).
H.C. Wainwright initiated coverage of Antares Pharma (NASDAQ:ATRS) with a “buy” rating and $5 price target. The stock closed at $3.01 on June 22.
Stryker (NYSE:SYK) has agreed to acquire Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) for $11.75 a share, implying a total equity value of approximately $701-million.
H.C. Wainwright launched coverage of Achaogen (NASDAQ:AKAO) with a “buy” rating and $29 price target. The stock closed at $22.11 on June 14.
Cantor Fitzgerald expanded its healthcare equity research team with the additions of Louise Chen and Travis Steed.
Tetra Bio-Pharma (OTCQB:TBPMF; CSE:TBP) and the New Brunswick Health Research Foundation are investing $500,000 each over five years to establish a health research chair in cannabis at the University of New Brunswick.
Knight Therapeutics’ (TSX:GUD) New Drug Submission (NDS) for Probuphine, a subdermal implant of buprenorphine for the treatment of opioid drug dependence, has been accepted for review by Health Canada.
H.C. Wainwright initiated coverage of XOMA (NASDAQ:XOMA) with a “buy” rating and $15 price target. The stock closed at $6.86 June 12th.
Recurrent glioblastoma (rGB) patients in Medicenna Therapeutics’ (TSXV:MDNA) Phase 2b clinical trial of MDNA55, a targeted immunotherapy agent, have been treated at three clinical centers in the U.S. using innovative drug delivery technology from Brainlab.